All Stories

  1. Efficient clinical decision-making process via AI-based multimodal data fusion: A COVID-19 case study
  2. Epidemiological characteristics of severe community-acquired pneumonia in children admitted to two tertiary hospitals in Shihezi, Xinjiang Region, China in 2023: a cross-sectional analysis
  3. Terapias respiratorias domiciliarias: documento técnico de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) de apoyo institucional a la toma de decisiones
  4. Comprehensive analysis of clinical data for COVID-19 outcome estimation with machine learning models
  5. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia
  6. Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection
  7. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease
  8. Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study
  9. Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study
  10. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation
  11. Correction to: Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
  12. COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation
  13. One Year of the COVID-19 Pandemic in Galicia: A Global View of Age-Group Statistics during Three Waves
  14. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia
  15. Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective
  16. Phenotypic characterisation of early COPD: a prospective case–control study
  17. Documento de consenso sobre el diagnóstico y tratamiento de la infección bronquial crónica en la enfermedad pulmonar obstructiva crónica
  18. Current events and action plans in the advancement of thoracic surgery and pulmonology in Spain
  19. Impact of a Home Telehealth Program After a Hospitalized COPD Exacerbation: A Propensity Score Analysis
  20. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
  21. Next-generation sequencing diagnosis of severe pneumonia from fulminant psittacosis with multiple organ failure: a case report and literature review
  22. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia
  23. Clasificación de la hipertensión arterial pulmonar basada en el estudio genético y familiar
  24. Factores que condicionan la pérdida de control al reducir escalones terapéuticos en el tratamiento del asma moderada-grave en la práctica clínica habitual: estudio español multicéntrico
  25. Classification of Pulmonary Arterial Hypertension by Genetic and Familial Testing
  26. EARLY COPD: determinantes de la aparición y progresión de la enfermedad pulmonar obstructiva crónica en adultos jóvenes. Protocolo de un estudio caso-control con seguimiento
  27. Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Case–Control Study With Follow-Up
  28. Influenza A H1N1 Community-Acquired Pneumonia: Characteristics and Risk Factors—A Case-Control Study
  29. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease
  30. An international perspective on hospitalized patients with viral community-acquired pneumonia
  31. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
  32. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  33. Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)? CON
  34. Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study
  35. Tratamiento con esteroides sistémicos en agudización grave de enfermedad pulmonar obstructiva crónica: empleo de pautas cortas en práctica clínica habitual y relación con la estancia hospitalaria
  36. High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis
  37. Discordance of physician clinical judgment vs. pneumonia severity index (PSI) score to admit patients with low risk community-acquired pneumonia: a prospective multicenter study
  38. Neumonía subaguda como manifestación de una neumonía organizada fibrosante aguda
  39. Relationship Between Severity Classification of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Clinical Outcomes in Hospitalized Patients
  40. Risk Factors of Poor Outcomes after Admission for a COPD Exacerbation: Multivariate Logistic Predictive Models
  41. Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis
  42. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study
  43. Surgical Lung Biopsy: The Role of Better Surgery
  44. Active strategy in primary care for diagnosing COPD
  45. Reversible Schamroth Sign
  46. Signo de Schamroth reversible
  47. Long-Term Noninvasive Ventilation Among Chronic Respiratory Failure Diseases (Cystic Fibrosis and Other Diseases) Awaiting Lung Transplantation: Key Determinants and Practical Implications
  48. Validación de la versión en español del cuestionario COPD-Q/EPOC-Q de conocimiento de la EPOC
  49. Validation of the Spanish Version of the COPD-Q Questionnaire on COPD Knowledge
  50. Community-Acquired Pneumonia Requiring Hospitalization
  51. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations
  52. Lung cancer in patients living with HIV infection
  53. Organized Pneumonia Secondary to Increasing Doses of Temozolomide
  54. Actualización de GesEPOC 2014 y corticoides sistémicos en la agudización de enfermedad pulmonar obstructiva crónica (EPOC)
  55. 2014 GesEPOC and Systemic Steroids in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation: An Update
  56. Empyema due to Aggregatibacter aphrophilus and Parvimonas micra Coinfection
  57. Empiema secundario a coinfección por Aggregatibacter aphrophilus y Parvimonas micra
  58. Chromogranin A levels and mortality in patients with severe sepsis
  59. Documento de consenso «Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva crónica»
  60. «Ojo» a los broncodilatadores en nebulización
  61. Beware of Nebulized Bronchodilators
  62. Using Standardized Care Bundles in the Emergency Department to Decrease Mortality in Patients Presenting with Community-Acquired Pneumonia (CAP) and Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
  63. Multicentric study on the beta-blocker use and relation with exacerbations in COPD
  64. Enfermedad pulmonar intersticial difusa como primera manifestación de macroglobulinemia de Waldenström: descripción de un caso y revisión de la literatura
  65. Diffuse Interstitial Lung Disease as a First Manifestation of Waldenström's Macroglobulinemia: Case Report and Review of the Literature
  66. Are Pseudomonas aeruginosa Risk Factors Associated With Pseudomonas Acute Exacerbation of COPD?
  67. Validation of the European Respiratory Society Guidelines for Pseudomonas aeruginosa Risk Factors in Patients With COPD Exacerbations
  68. Sternal Mass Presenting as a First Manifestation of Lung Cancer
  69. Lung cancer in HIV-infected patients
  70. Community-Acquired Pneumonia Team Decreases Length of Stay in Hospitalized, Low-Risk Patients With Pneumonia
  71. Lipoma endobronquial
  72. Sternal Mass Presenting as a First Manifestation of Lung Cancer
  73. Hypocapnia and Hypercapnia Are Predictors for ICU Admission and Mortality in Hospitalized Patients With Community-Acquired Pneumonia
  74. Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study
  75. Community acquired pneumonia: severity scores as an adjunct to clinical judgement
  76. De la exclusión a la certidumbre. El recorrido hacia el diagnóstico de la fibrosis pulmonar idiopática
  77. Long-term Follow-up in Patients Diagnosed and Treated for Pulmonary Tuberculosis: What Really Happened With the Lung Function?
  78. Protocolo diagnóstico del tromboembolismo pulmonar
  79. Enfermedad tromboembólica venosa y tromboembolismo pulmonar
  80. Editorial from Guest Editor [Hot topic: Community-Acquired Pneumonia: A Review of Uncommon Topics (Guest Editor: Pedro J. Marcos)]
  81. Macrolides in Community-Acquired Pneumonia: The Importance of the Non-Antimicrobial Effect
  82. Expected Good Prognosis Community Acquired Pneumonia(CAP):the Importance Of A Specialized Care In Order To Avoid Admissions.A Comparative Study
  83. Microepidemias de tuberculosis en 5 brotes escolares: importancia de la tipificación genética de las cepas en su evaluación e interpretación
  84. Síndrome de Lady Windermere
  85. Hemorragia pulmonar y síndrome antifosfolípido primario: aportación de un caso y revisión de la literatura
  86. Lady Windermere Syndrome
  87. The Importance of Genotyping of Strains for the Evaluation and Interpretation of 5 School-Based Epidemic Outbreaks of Tuberculosis
  88. Angiolipomatosis renal y linfangioleiomiomatosis, su relación con la enfermedad de Bourneville